| Code | CSB-RA847702MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Casdozokitug, targeting interleukin-27 (IL-27), a heterodimeric cytokine composed of EBI3 and p28 subunits. IL-27 is primarily produced by antigen-presenting cells and plays a complex immunoregulatory role, exhibiting both pro-inflammatory and anti-inflammatory properties depending on the cellular context. It modulates T cell differentiation, promotes Th1 responses, and regulates the production of IL-10 and other cytokines. Dysregulated IL-27 signaling has been implicated in various autoimmune and inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus, making it an important therapeutic target.
Casdozokitug is a clinical-stage therapeutic antibody designed to neutralize IL-27 activity and has been investigated for the treatment of autoimmune diseases. This biosimilar antibody provides researchers with a valuable tool for investigating IL-27-mediated immune responses, exploring disease mechanisms in autoimmune and inflammatory disorders, and conducting preclinical studies related to IL-27 pathway modulation.
There are currently no reviews for this product.